Calmare Therapeutics Inc

Calmare Therapeutics — Shareholder Meeting (August 2014)

29 slides from Calmare Therapeutics's shareholder meeting presentation, Aug 20, 2014

  1. Slide 1: Annual General Meeting August 2014

    Annual General Meeting August 2014 © 2014 Calmare Therapeutics, Inc..

  2. Slide 2: Forward-looking statements

    THIS PRESENTATION CONTAINS “FORWARD - LOOKING STATEMENTS” WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH FORWARD - LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS WHICH MAY CAUSE THE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF

  3. Slide 3: Our future … Our past …

    Our future … Our past …

  4. Slide 4: Bio-therapeutic company developing the Calmare Pain Therapy device

    We are a bio - therapeutic company focused on the development and commercialization of our proprietary and patented flagship medical product: the Calmare ® Pain Therapy device © 2014 Calmare Therapeutics, Inc..

  5. Slide 5: Headquartered in Fairfield, CT since 1968; OTCQX listed

    • h eadquartered in Fairfield, CT since 1968 • publicly traded and in good standing on the OTCQX (“ CTTC ”) • the exclusive holder of global distribution and sales rights of the Calmare pain therapy device: 510(k) clearance • a U.S . Dept. of Defense contractor: GSA No .: V797P - 4300b © 2014 Calmar

  6. Slide 6: © 2014 Calmare Therapeutics, Inc..

    © 2014 Calmare Therapeutics, Inc..

  7. Slide 7: I'm in pain every day

    ECALMARE 1'm in pain every day. That changed me. Made me a harder person, a worst person. And I'm alone.

  8. Slide 8: Chronic neuropathic pain is a major health issue

    © 2014 Calmare Therapeutics, Inc.. Chronic neuropathic pain is a major health issue with up to 25% of the US population suffering from chronic pain . To assess the degree of pain a patient is in, physicians and the FDA alike, use “The” Pain Scale.

  9. Slide 9: Prescription painkiller overdoses killed more than 6,000 people in 2010

    Prescription painkiller overdoses killed more than 6,000 people in the U.S. in 2010. © 2014 Calmare Therapeutics, Inc..

  10. Slide 10: Dr. David Borsook on lack of effective treatments

    Dr. David Borsook, MD. PhD Director of Pain, Children’s Hospital Mass General Hospital, Boston. Mass . “ We do not yet have medications or other treatments that can effectively alleviate chronic pain with speed or efficiency in the majority of patients . Doctors treat patients with a trial - and - e

  11. Slide 11: © 2014 Calmare Therapeutics, Inc..

    © 2014 Calmare Therapeutics, Inc..

  12. Slide 12: Proprietary, patented, non-invasive pain therapy device

    Our proprietary, patented, non - invasive medical device developed to treat high intensity oncologic and neuropathic pain without the harmful side effects of narcotic painkillers. • Immediate to prolonged pain relief • Procedure regimen : — 10 to 15 treatments over 2 weeks — 1 or 2 “Booster” treatme

  13. Slide 13: How Calmare therapy works

    1. Certified practitioners place surface electrodes on the patient’s skin close to the pain source in order to access their C - fiber 2. Our patented multi - processor sends algorithmically - derived pain messages to the brain along the patient’s C - fibers No known side effects reported in use with

  14. Slide 14: Pain indications treated

    1. Chemotherapy - Induced Peripheral Neuropathy (CIPN) 2. Chronic Regional Pain Syndrome (CRIP) 3. Failed Back Surgery Syndrome 4. Chronic Post - herpetic Neuralgia (Shingles) 5. Sciatic and Lumbar Pain 6. Low Back Pain (LBP) 7. Post - Surgical Pain 8. Brachial Plexus Pain 9. Phantom Limb Syndrome 1

  15. Slide 15: Calmare treatment pilot study results

    • 33 patients • P ilot study • T erminal cancer patients • S evere drug resistance • 10 treatments Marineo G et al International Congress Series 1255(203) 381 - 388 Calmare Treatment Pilot Study Results The pain was reduced to zero. © 2014 Calmare Therapeutics, Inc..

  16. Slide 16: Average daily CIPN scores with Calmare treatments

    © 2014 Calmare Therapeutics, Inc.. Ave. Daily CIPN Scores With Calmare Treatments Pachman D, Loprinzi C, et al. Proc ASCO 2014, submitted • 53% reduction in pain score from baseline to day 10 • a 44% reduction (6.0 to 3.3) in tingling • 37% reduction in numbness

  17. Slide 17: Calmare vs. Clonazepam

    Calmare v. Clonazepam : Drugs (control group) and one treated with Calmare (26/Drug – 26/ST) G. Marineo, T . Smith, et al, JPSM 2011 72 % of patients pain and drug free 20 % of patients on reduced drug dosages © 2014 Calmare Therapeutics, Inc..

  18. Slide 18: 64% reduction in pain score

    64% reduction in pain score Smith T. et al Journal of Pain And Symptom Management 2010 © 2014 Calmare Therapeutics, Inc..

  19. Slide 19: Clinician and institution commentary

    • Mayo Clinic: Charles Loprinzi, MD ( Third Annual Cancer Pain Conference) − “(Calmare) therapy looks very promising in 3 pilot trials; a randomized trial is in development” • Johns Hopkins Medical Institute: Tom Smith, MD ( Journal of Pain & Palliative Care Pharmacotherapy . 2013;27:359 – 364) − “…

  20. Slide 20: This market is how big?

    T his market is how big?

  21. Slide 21: Global pain management market

    $ 28 . 6 billion : Global pain management therapeutic market ( CAGR of 5 . 3 % between 2002 and 2010 ) 116 million : Amount of U . S . adults experiencing chronic pain daily 15 million : Amount U . S . adults suffering from neuropathic pain * CTI is targeting : 1% of the global market © 2014 Calmare

  22. Slide 22: Practice economics per patient

    Each New Patient : 12 treatments over 2 weeks Primary Treatment Cost: $250 per patient = $3,000 1 over 2 weeks (est.) Practice Income (per month): 12 patients $ 36,000 Product Leasing: $ 1,900 2 Monthly Profit: $ 34,100 1 Average per patient cost Nationwide. 2 5% interest, 60 month lease, Calmare Cr

  23. Slide 23: What happens now?

    What happens now?

  24. Slide 24: GSA contract and planned raises

    © 2014 Calmare Therapeutics, Inc.. GSA contract line item (1Q 2015) : - $2.0 billion (announced Aug 2014): $187 million available - $3.0 to 5.0 million in unused funds: available to pain (VA) Raise $8.0 million (2Q 2015) : $3.0 million bridge (4Q 2014) - $2.0 million – Pivotal Study (CIPN: 200 patie

  25. Slide 25: Sales channels and break-even

    A. Private practices in the United States - Nurse/Sales Rep duo B. U.S. military - Authorized GSA vendor C. International Calmare distributors - E urope, M id. E ast, N o. A frica - Far East and Oceana Break Even © 2014 Calmare Therapeutics, Inc.. 1 Device per Week

  26. Slide 26: Company progress

    @CALMARE Company progress ... v v 7 v 4 v Repaid senior Note? EMENA distributor ‘Substantively reduced “burn” Streamlining sales process New financing/lease options Raised operational funds v Key Hires: CFO US Sales Head EMENA Sales Head Product Marketing Military BPA specialist

  27. Slide 27: Financial data (select)

    @CALMARE Financial Data (select) Stock Price (5/23/14) esses e -- $0.42 52-week Hi-Lo $0.05 - $0.55 Ave. Daily Trading Vol. (3m) ... Market Cap (5/23/14) Shares Outstanding . Float Authorized Shares . a Total Revenues (TTM; a/o 10 14). $936,000 Total Debt (a/0 1. 14)....c.0 . $3.1 mi

  28. Slide 28: Our Board of Directors

    (ETALMARE Our Board of Directors

  29. Slide 29: Thank you!

    Thank you! Conrad mir President & CEO 973,798,8862 Direct, ‘omir@calmaretherapeutics.com an Rhodes cro 203.268.6044 imnodes@calmaratherapeutics.com ‘www calmaretherapeutics.com wwwiecalmare.net {© 2014 Compottive Tesnnoiogies. ne

CALMARE THERAPEUTICS — Shareholder Meeting (August 2014) on 6ix